159 related articles for article (PubMed ID: 8299119)
1. Poor induction of interleukin-2 receptor expression on CD8bright+ cells in whole blood cell cultures with CD3 mAb. Implications for immunotherapy with CD3 mAb.
Janssen RA; Heijn AA; The TH; de Leij L
Cancer Immunol Immunother; 1994 Jan; 38(1):53-60. PubMed ID: 8299119
[TBL] [Abstract][Full Text] [Related]
2. HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients.
Janssen RA; Buter J; Straatsma E; Heijn AA; Sleijfer DT; de Vries EG; Mulder NH; The TH; de Leij L
Cancer Immunol Immunother; 1993; 36(3):198-204. PubMed ID: 8439981
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of anti-CD3 monoclonal antibody-induced T-cell proliferation and interleukin-2 secretion by physiologic combinations of dexamethasone and prostaglandin E2.
Elliott L; Brooks W; Roszman T
Cell Mol Neurobiol; 1993 Dec; 13(6):579-92. PubMed ID: 7910781
[TBL] [Abstract][Full Text] [Related]
4. Purified human T cells stimulated with cross-linked anti-CD3 monoclonal antibody OKT3: rIL-1 is a co-stimulatory factor for CD4+CD29+CD45RA- T cells.
Panzer S; Geller RL; Bach FH
Scand J Immunol; 1990 Oct; 32(4):359-71. PubMed ID: 1700468
[TBL] [Abstract][Full Text] [Related]
5. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
[TBL] [Abstract][Full Text] [Related]
6. Coexpression of Fc gamma receptor IIIA and interleukin-2 receptor beta chain by a subset of human CD3+/CD8+/CD11b+ lymphocytes.
Zupo S; Azzoni L; Massara R; D'Amato A; Perussia B; Ferrarini M
J Clin Immunol; 1993 May; 13(3):228-36. PubMed ID: 7686565
[TBL] [Abstract][Full Text] [Related]
7. Increased cAMP and cAMP-dependent protein kinase activity mediate anti-CD2 induced suppression of anti-CD3-driven interleukin-2 production and CD25 expression.
Lin J; Gettys TW; Qin L; Chavin KD; Yang Q; Ding Y; Punch JD; Bromberg JS
Pathobiology; 1995; 63(4):175-87. PubMed ID: 8866788
[TBL] [Abstract][Full Text] [Related]
8. CD4-CD8- human T cells: phenotypic heterogeneity and activation requirements of freshly isolated "double-negative" T cells.
Bender A; Kabelitz D
Cell Immunol; 1990 Jul; 128(2):542-54. PubMed ID: 2141552
[TBL] [Abstract][Full Text] [Related]
9. Bispecific antibody-directed antitumor activity of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus interleukin 2.
Nishimura T; Nakamura Y; Takeuchi Y; Gao XH; Tokuda Y; Okumura K; Habu S
Jpn J Cancer Res; 1991 Nov; 82(11):1207-10. PubMed ID: 1836455
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta.
Rudick RA; Carpenter CS; Cookfair DL; Tuohy VK; Ransohoff RM
Neurology; 1993 Oct; 43(10):2080-7. PubMed ID: 8105424
[TBL] [Abstract][Full Text] [Related]
11. Response of bovine gammadelta T cells to activation through CD3.
Sathiyaseelan T; Rogers A; Baldwin CL
Vet Immunol Immunopathol; 2002 Dec; 90(3-4):155-68. PubMed ID: 12459163
[TBL] [Abstract][Full Text] [Related]
12. Effect of Pseudomonas aeruginosa exotoxin A on CD3-induced human T-cell activation.
Michalkiewicz J; Stachowski J; Barth C; Patzer J; Dzierzanowska D; Runowski D; Madalinski K
Immunol Lett; 1998 Apr; 61(2-3):79-88. PubMed ID: 9657258
[TBL] [Abstract][Full Text] [Related]
13. In vivo administration of anti-murine CD3 monoclonal antibody induces selective, long-term anergy in CD8+ T cells.
Woodle ES; Hussein S; Bluestone JA
Transplantation; 1996 Mar; 61(5):798-803. PubMed ID: 8607186
[TBL] [Abstract][Full Text] [Related]
14. Requirement of monocytes and T-helper cells during development of tumor cell cytotoxicity in targeted T cells.
Smans KA; Hoylaerts MF; De Broe ME
Cancer Immunol Immunother; 1994 Jan; 38(1):43-52. PubMed ID: 8299118
[TBL] [Abstract][Full Text] [Related]
15. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
[TBL] [Abstract][Full Text] [Related]
16. The regulation of phenotype and function of human liver CD3+/CD56+ lymphocytes, and cells that also co-express CD8 by IL-2, IL-12 and anti-CD3 monoclonal antibody.
Jin Y; Fuller L; Carreno M; Esquenazi V; Tzakis AG; Miller J
Hum Immunol; 1998 Jun; 59(6):352-62. PubMed ID: 9634197
[TBL] [Abstract][Full Text] [Related]
17. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.
Itoh K; Platsoucas CD; Balch CM
J Exp Med; 1988 Oct; 168(4):1419-41. PubMed ID: 3262710
[TBL] [Abstract][Full Text] [Related]
18. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
19. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
[TBL] [Abstract][Full Text] [Related]
20. The anti-T cell monoclonal antibody 9.3 (anti-CD28) provides a helper signal and bypasses the need for accessory cells in T cell activation with immobilized anti-CD3 and mitogens.
Baroja ML; Lorre K; Van Vaeck F; Ceuppens JL
Cell Immunol; 1989 Apr; 120(1):205-17. PubMed ID: 2539266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
